{"DataElement":{"publicId":"2737666","version":"1","preferredName":"Prior Hematopoietic Stem Cell Transplantation Therapeutic Procedure Type","preferredDefinition":"A description of the type of therapy prior to the hematopoietic stem cell transplantation.","longName":"PR_HSCT_TX_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2737656","version":"1","preferredName":"Prior Hematopoietic Stem Cell Transplantation Therapeutic Procedure Type","preferredDefinition":"Earlier in time or order._Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_The grafting of tissues from one individual to another or place to place within a single individual._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"PR_HSCT_TX_TP","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2737654","version":"1","preferredName":"Prior Hematopoietic Stem Cell Transplantation Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.):The grafting of tissues from one individual to another or place to place within a single individual.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C12551:C15342:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Hematopoietic Stem Cell","conceptCode":"C12551","definition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49823DCF-FD48-2FA2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBREXT","dateModified":"2008-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49823DCF-FD56-2FA2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2737660","version":"1","preferredName":"Prior Hematopoietic Stem Cell Transplantation Therapeutic Procedure Type","preferredDefinition":"Earlier in time or order._Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_The grafting of tissues from one individual to another or place to place within a single individual._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Type; a subdivision of a particular kind of thing.","longName":"PR_HSCT_TX_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Imatinib mesylate (Gleevec, Glivec)","valueDescription":"Imatinib Mesylate","ValueMeaning":{"publicId":"2737465","version":"1","preferredName":"Imatinib Mesylate","longName":"2737465","preferredDefinition":"The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib Mesylate","conceptCode":"C1687","definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C337-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"498193F6-ED17-49AC-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"498193F6-ED23-49AC-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Nilotinib (Tasigna)","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"2737467","version":"1","preferredName":"Nilotinib","longName":"2737467","preferredDefinition":"An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C391-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"498193F6-ED38-49AC-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Interferon","valueDescription":"INTERFERON","ValueMeaning":{"publicId":"2558977","version":"1","preferredName":"INTERFERON","longName":"2558977v1.00","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B36E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"498193F6-ED44-49AC-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Hydroxyurea (HU)","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"498193F6-ED59-49AC-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Dasatinib (Sprycel)","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"498193F6-ED6E-49AC-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Combination chemotherapy","valueDescription":"Combination Chemotherapy","ValueMeaning":{"publicId":"2737661","version":"1","preferredName":"Combination Chemotherapy","longName":"2737661","preferredDefinition":"Treatment using more than one anticancer drug.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combination Chemotherapy","conceptCode":"C191","definition":"Treatment using more than one anticancer drug.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498193F6-ED7C-49AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4DD75546-2768-2097-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-22","modifiedBy":"ALEYR","dateModified":"2008-05-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2737659","version":"1","preferredName":"Prior Hematopoietic Stem Cell Transplantation Therapeutic Procedure Type","preferredDefinition":"Earlier in time or order.:Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.):The grafting of tissues from one individual to another or place to place within a single individual.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Type; a subdivision of a particular kind of thing.","longName":"C25629:C12551:C15342:C49236:C2","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Hematopoietic Stem Cell","conceptCode":"C12551","definition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498193F6-ECE8-49AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBREXT","dateModified":"2008-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"498193F6-ECF9-49AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":" DefinedSubstanceAdministration:nameCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What type of treatment did th","type":"Preferred Question Text","description":"What type of treatment did the recipient receive prior to the hematopoietic stem cell transplantation (HSCT)?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2737666","type":"BRIDG Mapping Path","description":"\"PerformedDiagnosis > PerformedSubstanceAdministration [1] > DefinedSubstanceAdministration.nameCode WHERE PerformedDiagnosis.value = \"\"Chronic Myelogenous Leukemia(CML)\"\" AND PerformedSubstanceAdministration.dateRange [1] IS LESS THAN [transplant date}  {transplant date} is determiend by: PerformedDiagnosis > PerformedSubstanceAdministration.dateRange [2] WHERE PerformedSubstanceAdministration [2] > DefinedSubstranceAdministration.nameCode = \"\"Administer Hematopoietic Cell Product{ Transplantation}\"\"\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4981D9FF-1A02-5865-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"KUMMEROA","dateModified":"2021-04-30","changeDescription":". 2021-4-30 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}